PKD1L2

Across TCGA pan-cancer cohorts, PKD1L2 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated PKD1L2 data layer compared with 16 for mutation status.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PKD1L2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated PKD1L2 expression acts as an unfavorable survival marker, although some lineages such as ACC and SKCM show a favorable association.

ACC, KIRC, and LUAD are the cancer types where PKD1L2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.918	0.678	<.001	80	view →
KIRC	DFS	Median	All	0.492	0.732	<.001	71	view →
LUAD	DFS	Median	All	0.289	0.435	<.001	68	view →
SKCM	DFS	Median	II,III,IV	0.755	0.624	<.001	33	view →
CESC	OS	Tertile	IV	0.906	0.325	.001	30	view →
MESO	OS	Quartile	II,III,IV	0.568	0.301	.022	29	view →
BLCA	DFS	Median	III,IV	0.248	0.454	.008	24	view →
STAD	DFS	Tertile	II,III,IV	0.543	0.692	.007	22	view →
KIRP	DFS	Median	IV	0.762	0.044	.021	18	view →
PCPG	OS	Tertile	All	0.650	0.982	.002	17	view →
CHOL	OS	Median	III,IV	0.286	1.000	.008	15	view →
LIHC	OS	Median	All	0.693	0.859	<.001	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

PKD1L2–ACC (OS)

Open the ACC breakdown →